1 / 13

SMC Evaluation Project Laura McIver, Dr Paul Catchpole,

SMC Evaluation Project Laura McIver, Dr Paul Catchpole, On behalf of SMC Evaluation Management Group ABPI Conference, 17 th November 2006. Remit of Evaluation. To assess the impact and effectiveness of SMC Advice in NHS Scotland

tausiq
Télécharger la présentation

SMC Evaluation Project Laura McIver, Dr Paul Catchpole,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SMC Evaluation Project Laura McIver, Dr Paul Catchpole, On behalf of SMC Evaluation Management Group ABPI Conference, 17th November 2006

  2. Remit of Evaluation • To assess the impact and effectiveness of SMC Advice in NHS Scotland • To inform Scottish practice around managed introduction of new medicines • To contribute to the wider understanding of organisations that assess new technologies

  3. Project Team Links SMC Management group SMC reference group Project team: Bill Ramsay Marion Bennie Corri Black Vicky Cairns Sharon Hems Samuel Oduro NHS/Industry Groups/Networks

  4. Industry and Organisations represented on the Reference Group • Martin Coombes, AstraZeneca • Andrew McGuigan, Janssen-Cilag • Jim Swift, Takeda • Patient and Public Representative • Bipolar Fellowship Scotland • HIV Scotland • NHS ADTCs / Chief Executive / Director of Finance • University Academics • Scottish Executive Health Department

  5. Programme Elements SMC Evaluation Programme Impact of SMC decisions on medicines utilisation across the health care system. Evaluation of SMC budget forecasts with resource usage within NHS Scotland over time Evaluation of SMC’s engagement with key stakeholders Supporting linkage of clinical information and medicines utilisation data

  6. Classification of Medicines Accepted Restricted Unique Not Recommended Antimicrobials Cancer Data Sources and Collection • Primary care • - Information Services Division • Secondary Care • Pharmacy Systems and Clinicians • Pharmaceutical Industry • Data (either per month or per quarter) • volume/amount issued • total cost/expenditure for the medicine • no. of patients prescribed the medicine Medicine Utilisation Sample from each group selected. Reviewed and verified by clinical networks and Reference Group

  7. Medicine Utilisation Data Sources and Collection Analysis of data and draft report Validation and Interpretation via Clinical Networks, ADTC Networks, Reference Group and Industry Issue report

  8. Classification of Data

  9. Not Recommended Medicinesin Primary Care Restricted approval by NICE Not Recommended by SMC Note: GIC obtained from Prescribing Information System for Scotland (PRISMS)

  10. Outputs • Scottish patients access to individual medicines reviewed by SMC • Qualitative and quantitative data • Generic key findings / learnings • Recommendation next steps and actions

  11. SMC Evaluation Programme Evaluation of SMC’s engagement with key stakeholders. Patient and Public Involvement Sub-Group (PAPIG) Pharmaceutical Industry NHS ADTC role and processes reviewed Key themes identified Opportunity exists to share experience and identify examples of good practice Scottish Centre for Social Research

  12. Engagement with Industry • Industry can provide the project with important additional medicines uptake datasets: • Secondary care • Primary care • To support both primary analysis (mainly secondary care) and to cross validate and supplement existing NHS datasets • Evidence collection template (quantitative and qualitative data) presently being finalised for issue to companies

  13. Summary • Work programme progressing well and to plan • Challenges around data collection which can partially be addressed by engagement of industry • Validation and interpretation needs to be robust • Contextual qualitative evidence also required to support the quantitative information gathered • ABPI and industry support crucial to the project

More Related